Evidence map›Paper›PMID 42747566›Full record

ArticleMolecular biology reports2026

Integrated analysis of VEGFA rs833061 (- 460T > C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype-phenotype association.

Rohit Kaushik, Devender Pawar, Anuradha Sharma, Kiran Siwach, Gulshan Rohilla, Sonia Narwal, Nisha Khatri, Ankit Arora, Minakshi Vashist

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rohit KaushikDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Devender PawarDepartment of Urology, Pt. B.D. Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, Haryana, 124001, India.
Anuradha SharmaDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Kiran SiwachDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Gulshan RohillaDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Sonia NarwalDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Nisha KhatriDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Ankit AroraDepartment of Botany, Goswami Ganesh Dutt Sanatan Dharam PG College, Palwal, Haryana, India.
Minakshi VashistDepartment of Genetics, Maharshi Dayanand University, Rohtak, Haryana, 124001, India. mvashist14@mdurohtak.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAngiogenesis plays a central role in bladder cancer progression. VEGFA regulates angiogenesis, whereas YKL-40 is a pro-angiogenic biomarker. The relationship between VEGFA polymorphism and circulating YKL-40 remains unclear. METHODS AND

resultsA hospital-based case-control study involving 120 bladder cancer patients and 120 age- and sex-matched healthy controls was conducted. VEGFA rs833061 genotyping was performed using ARMS-PCR and confirmed by Sanger sequencing. Serum YKL-40 concentrations were measured by ELISA. Multivariable binary logistic regression analysis adjusted for age, sex, and smoking status demonstrated that the CT and TT genotypes remained independently associated with an increased risk of bladder cancer. Serum YKL-40 concentrations were significantly elevated in patients and increased progressively with tumor stage. TT genotype carriers exhibited the highest serum YKL-40 levels.

conclusionsAfter adjustment for age, sex, and smoking status, the VEGFA rs833061 polymorphism remained independently associated with bladder cancer susceptibility and circulating YKL-40 concentrations. These findings provide preliminary evidence of a genotype-phenotype relationship; however, validation in larger multicentre cohorts is required.

Indexed as

Chitinase-3-Like Protein 1Urinary Bladder NeoplasmsVascular Endothelial Growth Factor AAgedBiomarkers, TumorCase-Control StudiesFemaleGenetic Association StudiesGenetic Predisposition to DiseaseGenotypeHumansMaleMiddle AgedNeovascularization, PathologicPolymorphism, Single NucleotidePromoter Regions, GeneticBiomarkers, TumorCHI3L1 protein, humanChitinase-3-Like Protein 1Vascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisBladder cancerPolymorphismrs833061VEGFAYKL-40

Identifiers

PMID42747566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.